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CDI was associated with a trend for increased risk of mor-
tality (HR 2.36 [95% CI 0.98-5.71], P ¼ 0.06).
Conclusion: Use of antecedent antibiotics other than those
used to treat CDI was associated with an increased risk of
recurrent CDI in allogeneic HSCT recipients. CDI recurrence
rate is high in the ﬁrst 6months following ﬁrst episode of CDI
and is associated with a trend for increased risk of mortality.
This prompts the need for further investigation into sec-
ondary prophylaxis to prevent recurrent CDI.370
Clinical Proﬁle and Outcome of Patients with Graft
Rejection Following Related HLA Matched Allogeneic
Stem Cell Transplant for b Thalassemia Major
Vikram Mathews, Abhijeet Ganapule, Biju George,
Kavitha Lakshmi, Aby Abraham, Auro Viswabandya,
Alok Srivastava. Department of Haematology, Christian
Medical College, Vellore, India
Allogeneic stem cell transplant (SCT) remains the only
curative option for patients with b thalassemia major (TM).
Graft rejections post SCT are unfortunately a common
problem in this condition. There is limited data on the clin-
ical proﬁle and long term outcome of patients who have had
a graft rejection post allogeneic SCT.
From October, 1991 to April, 2013, 400 HLA matched related
transplants for TM was done at our center. The median age
was 8 years (range: 1-24) and there were 250 (62.5%) males.
154 (38.5%) were Lucarelli Class II and 229 (57.2%) were in the
Class III risk group. Majority (72%) received a busulfan based
conditioning regimen while 22% received a treosulfan based
regimen. Bone marrow was the source of stem cells in 81%
and PBSC in the rest.
There were 48 (12%) graft rejections in this cohort. Among
these 26 (54%) were primary graft failures (PGF) while 22
(46%) were secondary graft failures (SGF). The median time
to a SGF was 122 days (range: 40 - 2210). Of the 26 PGF,
9(34.6%) had autologous recovery with recurrence of trans-
fusion dependence while 17(65.4%) had pancytopenia.
11(42.3%) of PGF died prior to second transplant, 10 (38.5%)
had a second transplant and the rest had recurrence of TM
but were alive and well. Among the 22 SGF, 10(45.5%) had
autologous recovery. Of the SGF’s, 2 died prior to a second
transplant while 9 had a second transplant and the
remaining (n¼11) had recurrence of TM and were on con-
servative management.
Among the 29 cases that did not receive a second transplant
14 died at a median time of 20 days (range: 0-3268). The
major cause of death in this group was graft failure with
infection (n¼10) and regimen related toxicity (RRT; n¼4).
The remaining cases (n¼14) are alive and well on conser-
vative management (transfusion dependent, one with
pancytopenia).
19 (39.%) of the patients with graft rejection underwent a
second allogeneic SCT. Conditioning regimen for second SCT
was busulfan based in 5(26.3%), treosulfan based in 5(26.3%)
and the rest received non-myeloablative conditioning regi-
mens (ﬂudarabine based, low dose TBI, OKT3, Cy-OKT3) in
view of pancytopenia. The source of stem cells was BM in
7(36.84%) and PBSC in the rest. All cases conditioned with
treosulfan based regimen received a PBSC graft. The OS and
EFS of the patients that had a second transplant was
41.412.8% and 37.612.2% respectively. None of the patients
conditioned with a treosulfan based regimen died or had asecond graft rejection. Of the remaining 14 patients 11 died
of second graft rejection while 3 (all busulfan based condi-
tioning) are alive and well at 3, 23 and 81 months from
second transplant.
In conclusion graft rejection following allogeneic SCT for
patients with TM are associated with poor clinical outcomes.
A treosulfan based reduced toxicity myeloablative regimen
with a PBSC graft has potential to signiﬁcantly improve the
outcome in this group of patients.371
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Objective: To investigate the tolerance to 400 cGy of total
body irradiation (TBI) as part of a myeloablative conditioning
regimen for hematopoietic stem cell transplantation (HSCT)
and to identify factors inﬂuencing tolerance to TBI.
Patients and method: We conducted a prospective study
grading the tolerance to 400 cGy of TBI combined with Flu-
darabine and Busulfan as myeloablative-conditioning (Flu-
BuTBI) for HSCT. FluBuTBI consists of Fludarabine 50 mg/m2/
day x 5 days), Busulfan (3.2 mg/kg/day x 4 days) and total
body irradiation (200 cGy/day x 2 days). We also conducted
an exploratory analysis for factors affecting tolerance. Thirty-
six (36) patients received FluBuTBI. We graded tolerance to
TBI as Very Good (VG) e minor breaks during treatment
overall treatment time not doubled, Good (G) e important
breaks, treatment time at least doubled and Poor (P) emajor
breaks with clinical toxicity of E (emesis), D (diarrhea), or S
(syncopal episode). We grouped VG and G as one category
with 19 patients (VG¼12 + G¼7), and poor as the other
category (n¼16). We then analyzed age, sex, BMI, remission
status, comorbidity index, Karnofsky score comparing the 2
categories. Diagnoses included AML (n¼13), ALL (n¼4), NHL
(n¼13), Hodgkin lymphoma (n¼3) and CML (n¼1). Twenty
(20) patients underwent allogeneic and 16 autologous
transplant.
Results: Median age was 45 years in the VG/G category
versus 54 years in the P category (p¼0.11). 74% of patients in
the VG/G category were male versus 35% of patients in the P
category (p¼ 0.02). Heavily pre-treated was 37% in VG/G
category and 88% in the P category (p¼ 0.0009). The BMI was
identical in both the groups at 30. The HCT-CI was also
similar in both groups with medians of 1.6 (VG/G group) and
1.9 (P group). The Karnofsky scorewas 90 in both groups. 47%
of patients in the VG/G group and 41% of patients in the P
group were in complete remission. 74% patients in the VG/G
category underwent allogeneic transplant while only 29% of
patients in the P category did so (p¼0.002).
Conclusion: Our data shows that sex and prior therapy affect
tolerance to TBI. Males tolerated TBI better than females.
Patients who were heavily pretreated tolerated TBI less well.
Surprisingly, Karnofsky score, HCT-CI, disease and BMI had
no effect on the tolerance to TBI. Better prophylactic strategy
is warranted in the at risk population. Factors affecting
tolerance to TBI deserves further study in a larger cohort.
